Your browser doesn't support javascript.
Molecular and serological characterization of SARS-CoV-2 infection among COVID-19 patients.
Li, Linghua; Liang, Yuanhao; Hu, Fengyu; Yan, Huanchang; Li, Yueping; Xie, Zhiwei; Huang, Liping; Zhao, Jianhui; Wan, Zhengwei; Wang, Haiying; Shui, Jingwei; Cai, Weiping; Tang, Shixing.
  • Li L; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510060, China.
  • Liang Y; Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, 510515, China.
  • Hu F; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510060, China.
  • Yan H; Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, 510515, China.
  • Li Y; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510060, China.
  • Xie Z; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510060, China.
  • Huang L; Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, 510515, China.
  • Zhao J; Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, 510515, China.
  • Wan Z; Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, 510515, China.
  • Wang H; Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, 510515, China.
  • Shui J; Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, 510515, China.
  • Cai W; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510060, China.
  • Tang S; Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, 510515, China; Hospital of Dermatology, Southern Medical University, Guangzhou, China. Electronic address: tamgshixing@smu.edu.cn.
Virology ; 551: 26-35, 2020 12.
Article in English | MEDLINE | ID: covidwho-799506
Semantic information from SemMedBD (by NLM)
1. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
2. Severe Acute Respiratory Syndrome PROCESS_OF Patients
Subject
Severe Acute Respiratory Syndrome
Predicate
PROCESS_OF
Object
Patients
3. 2019 novel coronavirus CAUSES COVID-19
Subject
2019 novel coronavirus
Predicate
CAUSES
Object
COVID-19
4. Mild disorder PROCESS_OF Patients
Subject
Mild disorder
Predicate
PROCESS_OF
Object
Patients
5. Borg Category-Ratio 10 Perceived Exertion Score 5 PROCESS_OF Patients
Subject
Borg Category-Ratio 10 Perceived Exertion Score 5
Predicate
PROCESS_OF
Object
Patients
6. 2019 novel coronavirus PROCESS_OF Cohort
Subject
2019 novel coronavirus
Predicate
PROCESS_OF
Object
Cohort
7. Anti-Antibodies PART_OF 2019 novel coronavirus
Subject
Anti-Antibodies
Predicate
PART_OF
Object
2019 novel coronavirus
8. Quantitative Reverse Transcriptase PCR MEASURES RNA
Subject
Quantitative Reverse Transcriptase PCR
Predicate
MEASURES
Object
RNA
9. Quantitative Reverse Transcriptase PCR MEASURES Anti-Antibodies
Subject
Quantitative Reverse Transcriptase PCR
Predicate
MEASURES
Object
Anti-Antibodies
10. High Level PROCESS_OF Patients
Subject
High Level
Predicate
PROCESS_OF
Object
Patients
11. Antibodies ASSOCIATED_WITH Disease
Subject
Antibodies
Predicate
ASSOCIATED_WITH
Object
Disease
12. Body tissue LOCATION_OF 2019 novel coronavirus
Subject
Body tissue
Predicate
LOCATION_OF
Object
2019 novel coronavirus
13. Antibody Formation PROCESS_OF Patients
Subject
Antibody Formation
Predicate
PROCESS_OF
Object
Patients
14. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
15. Severe Acute Respiratory Syndrome PROCESS_OF Patients
Subject
Severe Acute Respiratory Syndrome
Predicate
PROCESS_OF
Object
Patients
16. 2019 novel coronavirus CAUSES COVID-19
Subject
2019 novel coronavirus
Predicate
CAUSES
Object
COVID-19
17. Mild disorder PROCESS_OF Patients
Subject
Mild disorder
Predicate
PROCESS_OF
Object
Patients
18. Borg Category-Ratio 10 Perceived Exertion Score 5 PROCESS_OF Patients
Subject
Borg Category-Ratio 10 Perceived Exertion Score 5
Predicate
PROCESS_OF
Object
Patients
19. 2019 novel coronavirus PROCESS_OF Cohort
Subject
2019 novel coronavirus
Predicate
PROCESS_OF
Object
Cohort
20. Anti-Antibodies PART_OF 2019 novel coronavirus
Subject
Anti-Antibodies
Predicate
PART_OF
Object
2019 novel coronavirus
21. Quantitative Reverse Transcriptase PCR MEASURES RNA
Subject
Quantitative Reverse Transcriptase PCR
Predicate
MEASURES
Object
RNA
22. Quantitative Reverse Transcriptase PCR MEASURES Anti-Antibodies
Subject
Quantitative Reverse Transcriptase PCR
Predicate
MEASURES
Object
Anti-Antibodies
23. High Level PROCESS_OF Patients
Subject
High Level
Predicate
PROCESS_OF
Object
Patients
24. Antibodies ASSOCIATED_WITH Disease
Subject
Antibodies
Predicate
ASSOCIATED_WITH
Object
Disease
25. Body tissue LOCATION_OF 2019 novel coronavirus
Subject
Body tissue
Predicate
LOCATION_OF
Object
2019 novel coronavirus
26. Antibody Formation PROCESS_OF Patients
Subject
Antibody Formation
Predicate
PROCESS_OF
Object
Patients
ABSTRACT

BACKGROUND:

SARS-CoV-2 is a novel coronavirus and the cause of COVID-19. More than 80% of COVID-19 patients exhibit mild or moderate symptoms. In this study, we investigated the dynamics of viral load and antibodies against SARS-CoV-2 in a longitudinal cohort of COVID-19 patients with severe and mild/moderate diseases.

METHODS:

Demographic and clinical information were obtained. Serial samples of blood, nasal and pharyngeal and anal swabs were collected at different time points post-onset. SARS-CoV-2 RNA and anti-SARS-CoV-2 antibodies were measured by qRT-PCR and immunoassays, respectively.

RESULTS:

Respiratory SARS-CoV-2 RNA was detectable in 58.0% (58/100) COVID-19 patients upon admission and lasted for a median of 13 days post-onset. In addition, 5.9% (1/17) and 20.2% (19/94) of the blood and anal swab specimens were positive for SARS-CoV-2 RNA, respectively. Anal viral RNA was more frequently detected in the patients who were positive for viral RNA in the respiratory samples upon admission. Specific anti-SARS-CoV-2 antibody developed within two weeks after onset, reached peak approximately 17 days post-onset and then maintained at relatively high level up to 50 days we analyzed in most patients. However, the levels of antibodies were variable among the patients. High titers of antibodies appeared to be associated with the severity of the disease. Furthermore, viral proteins from different sources showed significant difference of serological sensitivity especially during the first week post-onset.

CONCLUSIONS:

Our results indicate rapid clearance or self-elimination of viral RNA in about half of the COVID-19 patients upon admission. Viral RNA shedding of SARS-CoV-2 occurred in multiple tissues including the respiratory system, blood, and intestine. Variable levels of specific anti-SARS-CoV-2 antibody may be associated with disease severity. These findings have shed light on viral kinetics and antibody response in COVID-19 patients and provide scientific evidence for infection control and patient management.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Observational study / Risk factors Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: Virology Year: 2020 Document Type: Article Affiliation country: J.virol.2020.09.008

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Observational study / Risk factors Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: Virology Year: 2020 Document Type: Article Affiliation country: J.virol.2020.09.008